Today is a special day for Relay Therapeutics. The FDA has approved lirafugratinib (brand name LYRFIGTU™) for patients with FGFR2-driven #cholangiocarcinoma, brought to patients by our commercial partner Elevar Therapeutics following our global out-licensing agreement in 2024. This is the first medicine to emerge from our Dynamo® platform, our approach to studying protein motion with the goal of solving some of the toughest challenges in drug discovery. Relay was founded to make medicines for patients in need, and reaching an approval just 10 years later makes this a landmark validation for our R&D team's approach. Kudos and Yahzu to the dedicated Relayers who worked relentlessly to discover and develop this drug, congratulations to our partners at Elevar, and a sincere thank you to the patients, families, and investigators who have made this accomplishment possible.

Today, we announced that the US FDA has granted zovegalisib Breakthrough Therapy Designation for PIK3CA-mutant, HR+/HER2- advanced #breastcancer, supported by data from our ReDiscover trial testing zovegalisib at the 600mg BID fasted & 400mg BID fed doses in combo w/ fulvestrant.

We will present our preclinical work in #vascularmalformations at #VAC2025 today. As we advance our commitment to innovation, we’re preparing to initiate the Phase 1 clinical trial of RLY-2608 in PI3Kα-driven vascular malformations by the end of Q1. Congratulations Fabien & team!

Today, we announced positive interim data for RLY-2608 demonstrating clinically meaningful progression free survival for RLY-2608 in patients with HR+/HER2- #BreastCancer. President of R&D Dr. Don Bergstrom shares more about the significance of these data below. Tune into our conference call this morning, September 9, at 8:00AM ET for details. $RLAY ir.relaytx.com/news-releases…

🧵 (1/9) Today, beginning at 8AM, we will be live tweeting from our New Program & Platform Event. Check back here for real-time details on our new program disclosures and other exciting updates. See this morning’s press release and register for our live webcast here. ir.relaytx.com/events/event-… $RLAY

Today, we announced a clinical trial collaboration to develop RLY-2608 with atirmociclib, Pfizer’s next-generation selective CDK4 inhibitor currently in Phase 1 studies, in triplet combination in patients with PI3Kα-mutated, HR+, HER2-metastatic #breastcancer. Clinical start by YE 2024. Find full details here. ir.relaytx.com/news-releases… $RLAY